Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SAL0120 tablets in uncontrolled primary hypertension despite 2 or at least 3 antihypertensive drugs
CTR20242778Phase 2Active
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SAL0120 in essential hypertension, resistant hypertension (RH), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Oct 2024; status: active.
02
Drugs
SAL0120
03
Conditions
essential hypertensionresistant hypertension (RH)
Beyond the preview
Go deeper on CTR20242778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242778.